"MSG-01: A Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Prophylaxis Followed by Preemptive Therapy for Invasive Candidiasis in High-Risk Adults in the Critical Care Setting" by Luis Ostrosky-Zeichner

Article

MSG-01: A Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Prophylaxis Followed by Preemptive Therapy for Invasive Candidiasis in High-Risk Adults in the Critical Care Setting

Clinical Infectious Diseases (2014)

Luis Ostrosky-Zeichner, University of Texas Health Science Center at Houston
Shmuel Shoham, Johns Hopkins University
Jose Vazquez, Georgia Regents University
Annette Reboli, Rutgers University
Robert Betts, University of Rochester
Michelle A. Barron, University of Colorado Denver
Mindy Schuster, University of Pennsylvania
Marc A. Judson, Albany Medical College
Sanjay G. Revankar, Wayne State University
Juan Pablo Caeiro, Baylor College of Medicine
Julie E. Mangino, Ohio State University
David Mushatt, Tulane University
Roger Bedimo, University of Texas Southwestern Medical Center
Alison Freifeld, University of Nebraska Medical Center
Minh Hong Nguyen, University of Pittsburgh
Carol A. Kauffman, University of Michigan
William E. Dismukes, University of Alabama at Birmingham
Andrew O. Westfall, University of Alabama at Birmingham
Jeanna Beth Deerman
Craig Wood, Merck & Co.
Jack D. Sobel, Wayne State University
Peter G. Pappas, University of Alabama at Birmingham

Link

Disciplines

Publication Date

May 1, 2014

DOI

10.1093/cid/ciu074

Citation Information

Luis Ostrosky-Zeichner, Shmuel Shoham, Jose Vazquez, Annette Reboli, et al.. "MSG-01: A Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Prophylaxis Followed by Preemptive Therapy for Invasive Candidiasis in High-Risk Adults in the Critical Care Setting" Clinical Infectious Diseases Vol. 58 Iss. 9 (2014) p. 1219 - 1226
Available at: http://works.bepress.com/annette-reboli/12/